サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1519387

がん/腫瘍プロファイリング市場レポート：がんタイプ、技術、手法、用途、地域別、2024～2032年

Cancer/Tumor Profiling Market Report by Cancer Type, Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Immunohistochemistry, In-Situ Hybridization, Microarray, and Others), Technique, Application, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 147 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
がん/腫瘍プロファイリング市場レポート：がんタイプ、技術、手法、用途、地域別、2024～2032年
出版日: 2024年07月01日
発行: IMARC
ページ情報: 英文 147 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のがん/腫瘍プロファイリング市場規模は2023年に115億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに246億米ドルに達し、2024～2032年の間に8.6％の成長率（CAGR）を示すと予測しています。

がん/腫瘍プロファイリングは、バイオマーカー試験としても知られ、腫瘍組織サンプル中の特定のタンパク質、遺伝子、遺伝子変異（変化）、その他のバイオマーカーを同定するために使用される試験室での試験または手順を指します。患者の腫瘍の経路が利用可能な標的療法と一致するかどうかを判断する際に腫瘍医を支援します。また、日常的な診断、治療方針の決定、疾患の重症度やゲノムの蓄積別の個人に合わせた治療計画や治療法の開発にも役立ちます。がん/腫瘍プロファイリングはまた、個別化医療、研究、バイオマーカーの発見、スクリーニングと診断技術の開発にも幅広く応用されています。

がん/腫瘍プロファイリング市場動向：

がん/腫瘍プロファイリングは、腫瘍学研究や、薬剤設計、発見、開発の過程におけるバイオマーカーの発見に広く利用されています。その結果、世界中でがんが広く蔓延していることが市場成長を促進する主要因となっています。これに加えて、診断や腫瘍プロファイリングのためのバイオマーカーへの注目の高まりや、大衆の個別化医療への嗜好の変化が、製品需要を増大させています。さらに、腫瘍の検出と同定にかかる時間を短縮するための高度な技術開発のために、がん研究に対する政府の資金援助や支援が大幅に増加しています。これとともに、次世代シーケンシング（NGS）などの分子生物学技術の最近の進歩が、がん/腫瘍プロファイリングの採用を加速しています。さらに、製薬企業やバイオテクノロジー企業による、新規治療法や新薬設計技術の上市に向けた研究開発（R&D）活動への投資が増加していることも、市場の成長を後押ししています。臨床試験件数の増加、免疫測定技術の採用拡大、有利な償還政策、医療インフラの改善、技術の進歩など、その他の要因も市場に明るい展望をもたらしています。

本レポートで扱う主要質問

  • 2023年の世界のがん/腫瘍プロファイリング市場の市場規模は？
  • 2024～2032年の世界のがん/腫瘍プロファイリング市場の予想成長率は？
  • 世界のがん/腫瘍プロファイリング市場に与えたCOVID-19の影響は？
  • 世界のがん/腫瘍プロファイリング市場を牽引する主要因は？
  • 世界のがん/腫瘍プロファイリング市場のがんタイプ別の内訳は？
  • 世界のがん/腫瘍プロファイリング市場の主要地域は？
  • 世界のがん/腫瘍プロファイリング市場の主要参入企業/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブ概要

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界のがん/腫瘍プロファイリング市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：がんタイプ別

  • 乳がん
  • 肺がん
  • 大腸がん
  • 前立腺がん
  • メラノーマがん
  • その他

第7章 市場内訳：技術別

  • 次世代シーケンシング（NGS）
  • ポリメラーゼ連鎖反応（PCR）
  • 免疫組織化学（IHC）
  • in situーハイブリダイゼーション（ISH）
  • マイクロアレイ
  • その他

第8章 市場内訳：手法別

  • ゲノミクス
  • プロテオミクス
  • エピジェネティクス
  • メタボロミクス

第9章 市場内訳：用途別

  • 個別化医療
  • 診断
  • バイオマーカーの発見
  • 予測
  • その他

第10章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • Becton Dickinson and Company
    • Caris Life Sciences
    • Exact Sciences Corporation
    • F. Hoffmann-La Roche Ltd
    • Hologic Inc.
    • HTG Molecular Diagnostics Inc.
    • Illumina Inc.
    • Laboratory Corporation of America Holdings
    • NeoGenomics Laboratories
    • Qiagen N.V.
    • Siemens AG
    • Sysmex Corporation
図表

List of Figures

  • Figure 1: Global: Cancer/Tumor Profiling Market: Major Drivers and Challenges
  • Figure 2: Global: Cancer/Tumor Profiling Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Cancer/Tumor Profiling Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Cancer/Tumor Profiling Market: Breakup by Cancer Type (in %), 2023
  • Figure 5: Global: Cancer/Tumor Profiling Market: Breakup by Technology (in %), 2023
  • Figure 6: Global: Cancer/Tumor Profiling Market: Breakup by Technique (in %), 2023
  • Figure 7: Global: Cancer/Tumor Profiling Market: Breakup by Application (in %), 2023
  • Figure 8: Global: Cancer/Tumor Profiling Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Cancer/Tumor Profiling (Breast Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Cancer/Tumor Profiling (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Cancer/Tumor Profiling (Lung Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Cancer/Tumor Profiling (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Cancer/Tumor Profiling (Colorectal Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Cancer/Tumor Profiling (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Cancer/Tumor Profiling (Prostate Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Cancer/Tumor Profiling (Prostate Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Cancer/Tumor Profiling (Melanoma Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Cancer/Tumor Profiling (Melanoma Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Cancer/Tumor Profiling (Other Cancer Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Cancer/Tumor Profiling (Other Cancer Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Cancer/Tumor Profiling (Next-Generation Sequencing-NGS) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Cancer/Tumor Profiling (Next-Generation Sequencing-NGS) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Cancer/Tumor Profiling (Polymerase Chain Reaction-PCR) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Cancer/Tumor Profiling (Polymerase Chain Reaction-PCR) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Cancer/Tumor Profiling (Immunohistochemistry-IHC) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Cancer/Tumor Profiling (Immunohistochemistry-IHC) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Cancer/Tumor Profiling (In-Situ Hybridization-ISH) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Cancer/Tumor Profiling (In-Situ Hybridization-ISH) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Cancer/Tumor Profiling (Microarray) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Cancer/Tumor Profiling (Microarray) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Cancer/Tumor Profiling (Other Technologies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Cancer/Tumor Profiling (Other Technologies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Cancer/Tumor Profiling (Genomics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Cancer/Tumor Profiling (Genomics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Cancer/Tumor Profiling (Proteomics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Cancer/Tumor Profiling (Proteomics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Cancer/Tumor Profiling (Epigenetics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Cancer/Tumor Profiling (Epigenetics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Global: Cancer/Tumor Profiling (Metabolomics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Global: Cancer/Tumor Profiling (Metabolomics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Global: Cancer/Tumor Profiling (Personalized Medicine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Global: Cancer/Tumor Profiling (Personalized Medicine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Global: Cancer/Tumor Profiling (Diagnostics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Global: Cancer/Tumor Profiling (Diagnostics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Global: Cancer/Tumor Profiling (Biomarker Discovery) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Global: Cancer/Tumor Profiling (Biomarker Discovery) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Global: Cancer/Tumor Profiling (Prognostics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Global: Cancer/Tumor Profiling (Prognostics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Global: Cancer/Tumor Profiling (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Global: Cancer/Tumor Profiling (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: North America: Cancer/Tumor Profiling Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: North America: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: United States: Cancer/Tumor Profiling Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: United States: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Canada: Cancer/Tumor Profiling Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Canada: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Asia-Pacific: Cancer/Tumor Profiling Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Asia-Pacific: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: China: Cancer/Tumor Profiling Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: China: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Japan: Cancer/Tumor Profiling Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Japan: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: India: Cancer/Tumor Profiling Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: India: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: South Korea: Cancer/Tumor Profiling Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: South Korea: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Australia: Cancer/Tumor Profiling Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Australia: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Indonesia: Cancer/Tumor Profiling Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Indonesia: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Others: Cancer/Tumor Profiling Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Others: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Europe: Cancer/Tumor Profiling Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Europe: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Germany: Cancer/Tumor Profiling Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Germany: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: France: Cancer/Tumor Profiling Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: France: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: United Kingdom: Cancer/Tumor Profiling Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: United Kingdom: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Italy: Cancer/Tumor Profiling Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Italy: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Spain: Cancer/Tumor Profiling Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Spain: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Russia: Cancer/Tumor Profiling Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Russia: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Others: Cancer/Tumor Profiling Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 88: Others: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 89: Latin America: Cancer/Tumor Profiling Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 90: Latin America: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 91: Brazil: Cancer/Tumor Profiling Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 92: Brazil: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 93: Mexico: Cancer/Tumor Profiling Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 94: Mexico: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 95: Others: Cancer/Tumor Profiling Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 96: Others: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 97: Middle East and Africa: Cancer/Tumor Profiling Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 98: Middle East and Africa: Cancer/Tumor Profiling Market: Breakup by Country (in %), 2023
  • Figure 99: Middle East and Africa: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 100: Global: Cancer/Tumor Profiling Industry: SWOT Analysis
  • Figure 101: Global: Cancer/Tumor Profiling Industry: Value Chain Analysis
  • Figure 102: Global: Cancer/Tumor Profiling Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cancer/Tumor Profiling Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Cancer/Tumor Profiling Market Forecast: Breakup by Cancer Type (in Million US$), 2024-2032
  • Table 3: Global: Cancer/Tumor Profiling Market Forecast: Breakup by Technology (in Million US$), 2024-2032
  • Table 4: Global: Cancer/Tumor Profiling Market Forecast: Breakup by Technique (in Million US$), 2024-2032
  • Table 5: Global: Cancer/Tumor Profiling Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 6: Global: Cancer/Tumor Profiling Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Cancer/Tumor Profiling Market: Competitive Structure
  • Table 8: Global: Cancer/Tumor Profiling Market: Key Players
目次
Product Code: SR112024A5231

The global cancer/tumor profiling market size reached US$ 11.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 24.6 Billion by 2032, exhibiting a growth rate (CAGR) of 8.6% during 2024-2032.

Cancer/tumor profiling, also known as biomarker testing, refers to a laboratory test or procedure used to identify specific proteins, genes or gene mutations (changes) and other biomarkers in a tumor tissue sample. It assists oncologists in determining if the pathways of a patient's tumor match up with the available targeted therapies. It also aids in routine diagnostics, therapeutic decision-making, and developing personalized treatment plans and therapies for individuals based on the severity of their ailment and genomic build-up. Cancer/tumor profiling also finds extensive applications in personalized medicine, research, the discovery of biomarkers, and the development of screening and diagnostic techniques.

Cancer/Tumor Profiling Market Trends:

Cancer/tumor profiling is widely used in oncology research and discovery of biomarkers during the process of drug design, discovery and development. As a result, the widespread prevalence of cancer across the globe represents the primary factor driving the market growth. Besides this, the growing focus on biomarkers for diagnosis and tumor profiling and the shifting preferences toward personalized medicine among the masses are augmenting the product demand. Additionally, there has been a significant rise in government funding and support for cancer research for the development of advanced techniques to reduce the time taken for the detection and identification of tumors. Along with this, the recent advancements in molecular biology techniques, such as next-generation sequencing (NGS), are accelerating the adoption of cancer/tumor profiling. Furthermore, the increasing investments by pharmaceutical and biotechnology companies in research and development (R&D) activities for the launch of novel therapies and new drug designing techniques are propelling the market growth. Other factors, including the rising number of clinical trials, growing adoption of immunoassay techniques, favorable reimbursement policies, improving healthcare infrastructure, and technological advancements, are also creating a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global cancer/tumor profiling market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on cancer type, technology, technique and application.

Breakup by Cancer Type:

Breast Cancer

Lung Cancer

Colorectal Cancer

Prostate Cancer

Melanoma Cancer

Others

Breakup by Technology:

Next-Generation Sequencing (NGS)

Polymerase Chain Reaction (PCR)

Immunohistochemistry (IHC)

In-Situ Hybridization (ISH)

Microarray

Others

Breakup by Technique:

Genomics

Proteomics

Epigenetics

Metabolomics

Breakup by Application:

Personalized Medicine

Diagnostics

Biomarker Discovery

Prognostics

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Becton Dickinson and Company, Caris Life Sciences, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd, Hologic Inc., HTG Molecular Diagnostics Inc., Illumina Inc., Laboratory Corporation of America Holdings, NeoGenomics Laboratories, Qiagen N.V., Siemens AG and Sysmex Corporation.

Key Questions Answered in This Report

  • 1. What was the size of the global cancer/tumor profiling market in 2023?
  • 2. What is the expected growth rate of the global cancer/tumor profiling market during 2024-2032?
  • 3. What has been the impact of COVID-19 on the global cancer/tumor profiling market?
  • 4. What are the key factors driving the global cancer/tumor profiling market?
  • 5. What is the breakup of the global cancer/tumor profiling market based on the cancer type?
  • 6. What is the breakup of the global cancer/tumor profiling market based on the technique?
  • 7. What are the key regions in the global cancer/tumor profiling market?
  • 8. Who are the key players/companies in the global cancer/tumor profiling market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cancer/Tumor Profiling Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Cancer Type

  • 6.1 Breast Cancer
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Lung Cancer
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Colorectal Cancer
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Prostate Cancer
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Melanoma Cancer
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Next-Generation Sequencing (NGS)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Polymerase Chain Reaction (PCR)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Immunohistochemistry (IHC)
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 In-Situ Hybridization (ISH)
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Microarray
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Technique

  • 8.1 Genomics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Proteomics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Epigenetics
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Metabolomics
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Personalized Medicine
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Diagnostics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Biomarker Discovery
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Prognostics
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Becton Dickinson and Company
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Caris Life Sciences
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Exact Sciences Corporation
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 F. Hoffmann-La Roche Ltd
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6 Hologic Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 HTG Molecular Diagnostics Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
    • 15.3.8 Illumina Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Laboratory Corporation of America Holdings
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 NeoGenomics Laboratories
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
    • 15.3.11 Qiagen N.V.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Siemens AG
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Sysmex Corporation
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis